WITHDRAWN: FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma
FDA announced its final decision to withdraw approval of melphalan flufenamide (Pepaxto) with dexamethasone to treat certain patients with multiple myeloma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 23, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA issues final decision to withdraw approval of Pepaxto (melphalan flufenamide)
FDA has announced its decision to withdraw approval of Pepaxto (melphalan flufenamide), which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 23, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 21, 2024 Category: Drugs & Pharmacology Source Type: news
Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma
(MedPage Today) -- Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized trial showed.
After 4 years of follow-up, neither... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 21, 2024 Category: Hematology Source Type: news
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tecvayli (teclistamab-cqyv) for a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 20, 2024 Category: Drugs & Pharmacology Source Type: news
Patients see first savings from Biden ’s drug price push, as Pharma lines up its lawyers
Last year alone, David Mitchell paid $16,525 for 12 little bottles of Pomalyst, one of the pricey medications that treat his multiple myeloma, a blood cancer he was diagnosed with in 2010. The drugs have kept his cancer at bay. But their rapidly increasing costs so infuriated Mitchell that he was…#davidmitchell #pomalyst #affordabledrugs #medicare #kff #ira #cms #astrazeneca #pascalsoriot #robinfeldman (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2024 Category: Consumer Health News Source Type: news
Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma
FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 9, 2024 Category: Pharmaceuticals Source Type: news
Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma
The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Pulled Myeloma Drug May Have a Role in Treating the Disease After All
(MedPage Today) -- A little more than a year after belantamab mafodotin (Blenrep), an anti-B-cell maturation antigen (BCMA) monoclonal antibody, was withdrawn from the market for patients with relapsed/refractory multiple myeloma, results from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2024 Category: Hematology Source Type: news
Renowned Actor and Artist Ice-T Works Alongside the International Myeloma Foundation to Raise Awareness of Multiple Myeloma in the African American Community …
STUDIO CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Working alongside the International Myeloma Foundation (IMF), American songwriter, actor, producer, and well-known artist Ice-T is on a mission to help raise awareness of multiple myeloma in the African American community. Multiple myeloma is…#africanamerican #africanamericans #mediasnippet #tripletstransplants #myelomapower #mpowering #blackhistorymonth #imf #timessquare #newyorkcity (Source: Reuters: Health)
Source: Reuters: Health - February 1, 2024 Category: Consumer Health News Source Type: news
Young Myeloma Specialist Forges Ahead, Gives Back Young Myeloma Specialist Forges Ahead, Gives Back
" Manni " Mohyuddin, MD, reflects on patient needs, compassionate care, medical education, and recent advances in treating multiple myeloma.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Risk Factors ID'd for Monoclonal Gammopathy of Undetermined Significance
FRIDAY, Jan. 19, 2024 -- For individuals at increased risk for multiple myeloma, risk factors associated with mass spectrometry (MS) monoclonal gammopathy of undetermined significance (MGUS) include obesity, heavy smoking, and short sleep duration,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2024 Category: Pharmaceuticals Source Type: news
John Cadwallader has hope, time and new options after CAR-T treatment for multiple myeloma
John Cadwallader shares his journey of hope and perseverance after CAR-T cell therapy. "Every day is a gift," says John Cadwallader reflecting from his hospital room. For 10 years, the Welsh-born farmer and craftsman has been fighting multiple myeloma: a cancer that affects plasma cells which produce disease- and infection-fighting antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 10, 2024 Category: Databases & Libraries Source Type: news
Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma
(MedPage Today) -- Data presented at the 2023 American Society of Hematology (ASH) annual meeting demonstrated that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2024 Category: Hematology Source Type: news
Doctors said there was no treatment for John's cancer - now he's proved them wrong
In April 2012, John Cadwallader - an environmental engineer and father of two - was in such a daze he can't recall hearing the word 'myeloma', a type of blood cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - January 2, 2024 Category: Consumer Health News Source Type: news
